It is made available under a CC-BY-NC-ND 4.0 International license .

1

1 Improving Differentiation of Crohn's Disease and Ulcerative Colitis Proteomes through

2 **Protein-Wide Association Study Feature Selection in Machine Learning**

- 3 Running Title: Protein-Wide Association and Machine Learning in IBD
- Mark G. Gorelik^{1,2}, Aaron J. Gorelik³, Skye R.S. Fishbein^{1,2}, Tara Fehlmann⁴, Parakkal
 Deepak^{5#}, Ryan Bogdan³, Gautam Dantas^{1,2,6,7,8 #}, Umang Jain^{1#*} and SPARC IBD
 Investigators⁹
- ⁷ ¹Department of Pathology and Immunology, Washington University School of Medicine, St.
- 8 Louis, MO, USA
- ²The Edison Family Center for Genome Sciences and Systems Biology, Washington University
- 10 School of Medicine, St. Louis, MO, USA
- ³Department of Psychological & Brain Sciences, Washington University in St. Louis, St. Louis,
 MO, USA
- ⁴ Crohn's and Colitis Foundation, New York, New York, USA
- ⁵Division of Gastroenterology, John T. Milliken Department of Medicine, Washington University
- 15 School of Medicine, St. Louis, MO, USA
- ⁶Department of Molecular Microbiology, Washington University School of Medicine, St. Louis,
- 17 MO, USA
- ⁷Department of Biomedical Engineering, Washington University in St Louis, St. Louis, MO, USA
- ⁸Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA
- ⁹See below for SPARC-IBD Investigator Affiliations
- 21 #-co-senior authors

It is made available under a CC-BY-NC-ND 4.0 International license .

2

SPARC-IBD Investigators Site

Site	Principal Investigator
Baylor College of Medicine	Richa Shukla, MD
Baylor University Medical Center	Themistocles Dassopoulos, MD
Brigham & Women's Hospital	Scott B. Snapper, MD, PhD Joshua R. Korzenik, MD
Indiana University	Matthew Bohm, MD
Mayo Clinic	Laura Raffals, MD
Medical College of Wisconsin	Poonam Beniwal-Patel, MD
NYU Langone Medical Center	David Hudesman, MD
Scripps Healthcare	Mazer Ally, MD Gauree Konijeti, MD Rebecca Matro, MD
University Gastroenterology	Sheldon Lidofsky, MD
University of Alabama	Kirk Russ, MD
University of Cincinnati Medical Center	Loren Brook, MD
University of Chicago	Joel Pekow, MD
University of Maryland	Raymond Cross, MD
University of Michigan	Shrinivas Bishu, MD
University of Pennsylvania	Meenakshi Bewtra, MD, MPH, PhD James D Lewis, MD, MSCE
University of Pittsburgh	Richard Duerr, MD
University of Wisconsin	Sumona Saha MD, MS Freddy Caldera DO, MS
Vanderbilt University Medical Center	Elizabeth Scoville, MD, MSCI
Washington University School of Medicine	Parakkal Deepak, MBBS, MS

- 22
- 23
- 24

3

Funding information: This work is supported by SPARC IBD PLEXUS Grant from Crohn's & Colitis Foundation and NIH Washington University-DDRCC Grant Number P30 DK052574 to U.J. M.G.G and S.R.F are supported by awards from the Pediatric Gastroenterology Research Training Program (T32 DK077653). A.J.G is supported by NSF (DGE-213989). PD is supported by a Junior Faculty Development Award from the American College of Gastroenterology and IBD Plexus of the Crohn's & Colitis Foundation.

31 Presentation at a meeting: A portion of this study was presented at the 2024 Digestive and
32 Diseases Week (May 18-21) in Washington D.C.

33

34 Acknowledgements: The authors would like to thank Sarah E. Paul for her initial analytical 35 support and Kevin S. Blake of the LGM Scientific Editing Service at the Department of 36 Pathology and Immunology, Washington University School of Medicine for scientific editing 37 support. The authors also thank the staff at The Edison Family Center for Genome Sciences & 38 Systems Biology at the Washington University School of Medicine in St Louis, including E. 39 Martin and B. Koebbe for computational support, and B. Dee, K. Matheny, J. Theodore and K. 40 Page for administrative support. Finally, we would like to thank the members of the Dantas, 41 Bogdan, and Jain labs for helpful general discussions and comments on the manuscript. The 42 results published here are in whole based on data from the Study of a Prospective Adult 43 Research Cohort with IBD (SPARC IBD). SPARC IBD is a component of the Crohn's & Colitis 44 Foundation's IBD Plexus data exchange platform. SPARC IBD enrolls patients with an 45 established or new diagnosis of IBD from sites throughout the United States and links data 46 collected from the electronic health record and study specific case report forms. Patients also 47 provide blood, stool and biopsy samples at selected times during follow-up. The design and 48 implementation of the SPARC IBD cohort has been previously described¹. The SPARC IBD data

It is made available under a CC-BY-NC-ND 4.0 International license .

4

49	are available upon approved application to Crohn's & Colitis Foundation IBD Plexus
50	(https://www.crohnscolitisfoundation.org/ibd-plexus).
51	
52	Conflict of Interest. PD: has received research support under a sponsored research
53	agreement unrelated to the data in the paper and/or consulting from AbbVie, Arena
54	Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Pfizer, Prometheus
55	Biosciences, Takeda Pharmaceuticals, Roche Genentech, Scipher Medicine, Fresenius Kabi,
56	Teva Pharmaceuticals, Landos Pharmaceuticals, Iterative scopes and CorEvitas, LLC. U.J. has
57	received research support from Boehringer Ingelheim.
58	
59	Ethics Approval. The study protocol was approved by the Institutional Review Board (IRB) at
60	the University of Pennsylvania which is the single IRB for the SPARC IBD study.
61	
62	Author contributions: M.G.G., P.D., R.B., G.D. and U.J designed the study, T.F., P.D., and U.J.
63	collected and acquired data, M.G.G., A.J.G., S. R.S.F., and T.F.analysed data, M.G.G., and U.J
64	wrote the manuscript. All authors approved the manuscript.
65	
66	Abbreviations: Inflammatory bowel diseases (IBD), Protein-Wide Association Study (PWAS),
67	Crohn's disease (CD), Ulcerative colitis (UC)
68	
69	
70	
71	
72	
73	Abstract:

It is made available under a CC-BY-NC-ND 4.0 International license .

5

Background and Aims: Diagnostic differentiation between Crohn's disease (CD) and ulcerative colitis (UC) is crucial for timely and suitable therapeutic measures. The current gold standard for differentiating between CD and UC involves endoscopy and histology, which are invasive and costly. We aimed to identify blood plasma proteomic signatures using a Protein-Wide Association Study (PWAS) approach to differentiate CD from UC and evaluate the efficacy of these signatures as features in machine learning (ML) classifiers.

Methods: Among participants (n=1,106; n_{CD}=636; n_{UC}=470) of the Study of a Prospective Adult Research Cohort with IBD (SPARC), plasma protein (n=2,920) levels were estimated using Olink proteomics. A PWAS with Bonferroni correction for multiple testing was used to identify proteins associated with disease states after controlling for age, sex, and disease severity. ML classifiers examined the diagnostic utility of these models. Feature importance was determined via SHapley Additive exPlanations (SHAP) analysis.

Results: Thirteen proteins which were significantly differentially abundant in CD vs UC (all $|\beta|$ s > 0.22, all adjusted p values < 8.42E-06). Random forest models of proteins differentiated between CD and UC with models trained only on PWAS identified proteins (Average ROC-AUC 0.73) outperforming models trained of the full proteome (Average ROC-AUC 0.62). SHAP analysis revealed that Granzyme B, insulin-like peptide 5 (INSL5), and interleukin-12 subunit beta (IL-12B) were the most important features.

92 **Conclusions**: Our findings demonstrate that PWAS-based feature selection approaches are a 93 powerful method to identify features in complex, noisy datasets. Importantly, we have identified 94 novel peptide based biomarkers such as INSL5, that can be potentially used to complement 95 existing strategies to differentiate between CD and UC.

96

97 Keywords: Machine Learning, PWAS, IBD

- 98
- 99

6

100 INTRODUCTION

Inflammatory bowel diseases (IBD) are chronic relapsing and remitting inflammatory 101 102 disorders of the gastrointestinal tract. They affect more than 6 million people worldwide, and in 103 the United States alone more than 70,000 cases of IBD are diagnosed each year^{2,3}. Patients 104 with IBD experience markedly decreased quality of life, high disease- and treatment-related morbidity, and often endure complications requiring hospitalizations and surgeries^{4–8}. IBD is 105 106 generally subtyped as either Crohn's disease (CD) or ulcerative colitis (UC), with each differing in the areas of manifestation and the resulting sequela^{9–11}. Specifically, CD can affect any region 107 108 of the gastrointestinal (GI) tract and generally presents with transmural inflammation, while UC is restricted to the colon and is characterized by mucosal ulceration^{9–11}. While CD and UC 109 110 present distinct clinical complications, CD's ability to affect any region of the GI tract, including regions affected by UC, makes discriminating between them challenging¹²⁻¹⁴. 111

112 As each disease requires distinct therapeutic strategies, being able to accurately and 113 efficiently differentiate CD from UC has significant consequences for clinical care. For example, surgery is not a definitive cure for CD and can result in further complications^{15–19}. Current 114 115 practices rely on endoscopy to discriminate CD from UC; however, endoscopy is invasive, expensive, and carries significant risk to the patient²⁰. To complement endoscopic procedures, 116 117 blood and fecal markers are often used; however, none of these tests have proven sufficient to enable the differentiation of CD and UC^{21-27} . For instance, serum antibodies against 118 119 Saccharomyces cerevisiae (ASCA) and bacterial antigens have limited accuracy and suffer from low sensitivity, rendering these tests relatively nonspecific to subtype IBD²¹⁻²⁴. Other markers 120 121 such as fecal calprotectin and Lipocalin-2 can identify inflammatory status but do not enable differentiation between CD and UC^{25–27}. Given the rising prevalence of IBD worldwide, its high 122 123 morbidity, and its substantial negative impact on guality of life, there is an urgent need for

It is made available under a CC-BY-NC-ND 4.0 International license .

7

diagnostic tools that enable early differentiation of CD from UC, and are easier to use, non invasive, and less costly than those currently available²⁸.

126 Advanced proteomics technologies offer novel avenues for comprehending 127 pathophysiological mechanisms and pinpointing potential clinical biomarkers in complex 128 diseases. Recent breakthroughs, exemplified by the Olink platform, have revealed novel protein biomarkers for multiple diseases in blood and plasma^{29,30,31}, ensuring heightened sensitivity, 129 130 precision, and specificity, while also requiring minimal sample volumes. The output data of the 131 Olink platform can be then applied as features for machine learning (ML)-based classification analysis³². Unfortunately, even with these technological advancements, omics data is still often 132 affected by the "curse of dimensionality"³³, where the number of features captured far exceeds 133 the number of samples which can result in models fitting to spurious patterns³³. ML models 134 135 trained on high dimensionality data may fail to generalize to real world data unless the sample size is sufficiently large enough (normally at least 5 samples per feature³⁴) to separate signal 136 versus noise³³. However, generating such large omics datasets can be both costly and time 137 138 consuming. To mitigate the "curse of dimensionality" without the costly and time-consuming 139 process of generating large omics datasets, feature selection methods are often used to identify informative features in high dimensionality datasets before model training^{33,35}. In particular, 140 141 GWAS (Genome-Wide Association Study) and PheWAS (Phenome-Wide Association Study) approaches have proven to be extremely effective for feature selection³⁵. Here we leverage a 142 143 PWAS (Protein-Wide Association Study)-based approach to identify informative features in a 144 high dimensionality Olink proteomics dataset from IBD patients. This approach identified 13 145 proteins which distinguish CD from UC using plasma samples.

146

147

It is made available under a CC-BY-NC-ND 4.0 International license .

8

149 MATERIALS & METHODS

150 Participants and Sample Collection

The Study of Prospective Adult Research Cohort of IBD (SPARC IBD) is an ongoing longitudinal cohort study of patients with IBD recruited from 17 academic medical centers across the United States¹. Plasma samples used in this study were obtained from N = 1106 individuals ($n_{CD} = 636$; $n_{UC} = 470$).

155 Demographic, disease-related, and patient-reported data were collected during the 156 following visits: 1) during routine GI office visits (2016-2021), 2) guarterly by sending surveys to 157 patients, and 3) before a scheduled colonoscopy. All collections generated highly structured 158 electronic case report forms (eCRF). Bio-samples of each respective patient's blood and stool 159 were collected at enrolment and at the time of each patient's colonoscopy. Further, blood 160 samples were collected if a patient or provider reported key medication changes. Initially 161 collected samples were used in this study. Clinical data is transferred from sites on a periodic 162 basis and stored in IBD Plexus, Crohn's & Colitis Foundation's exchange platform (see¹ for 163 details).

164 Olink Proteomics, normalization, and filtering

165 Plasma was purified from blood and stored in EDTA. Proteins within plasma were 166 estimated using Olink Explore 384 panels (i.e., Cardiometabolic, Cardiometabolic II, 167 Inflammation, Inflammation II, Neurology, Neurology II, Oncology, Oncology II panels; Olink 168 Proteomics) Protein levels were estimated as Olink's arbitrary units, Normalized Protein 169 eXpression (NPX) values on a log₂ scale. NPX values which did not pass the following quality 170 control metrics were filtered out: 1) at least 500 counts per specific combination of sample and 171 assay, 2) the deviation from the median value of the incubation- and amplification controls for 172 each individual sample did not exceed +/-0.3 NPX for either of the internal controls, and 3) the 173 deviation of the median of the negative controls must be ≤5 standard deviations from the set 174 predefined manufacturer value. Samples across plates were normalized via the intensity

It is made available under a CC-BY-NC-ND 4.0 International license .

9

- 175 normalization method. The following Explore 384 assays did not meet Olink's batch release
- 176 quality control criteria and are therefore not included in this study: KNG1 (Inflammation II),
- 177 TNFSF9 (Inflammation II), TOM1L2 (Neurology II), SMAD1 (Oncology), and ARHGAP25
- 178 (Oncology).
- 179 Statistical Analyses
- 180 Protein Wide Association Study (PWAS)
- 181 A Protein Wide Association Study (PWAS) was performed on all proteins passing quality control
- described above (n=2,920) using the glmer function in the lme4 package³⁶ as previously
- 183 described in phenome-wide association studies^{37,38}. . CD/UC disease status was regressed on
- 184 each individual protein in a mixed effects logistic regression with age and sex as fixed effects
- 185 covariates and disease activity (Simple Crohn's Disease Activity Index for CD and 6-point Mayo
- 186 Score for UC¹) was treated as a random effect. To adjust for multiple testing, a Bonferroni-
- 187 corrected proteome wide significance threshold was used (0.05/2, 920 = 0.0000171 alpha
- 188 level).

189 <u>Principle Component Analysis (PCA)</u>

Principal component analysis (PCA) was initially performed incorporating the measured
 values of all proteins and just proteins identified via the PWAS analysis. Analysis of Similarities

192 (ANOSIM) was performed using the ANOSIM function in the vegan package³⁹.

193 Machine Learning Methods

194 Using Scikit learn based implementations of random forests we tested the following

- 195 feature sets: All proteomics features and patient features (Age, Sex, Disease Severity),
- 196 proteomics features which passed the Bonferroni cutoff and patient features, and just
- 197 proteomics features. Of the samples, 20% were reserved for a holdout validation dataset which
- 198 was also used for SHAP value analysis⁴⁰. The remaining 80% of the data was split into a
- 199 train/test split (70/30) and cross validated 30 times.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 200 The following packages and versions were used for analysis in R v4.3.2: ibdplexus (0.1.0),
- tidyverse (1.3.1), stringr (1.5.1), readxl (1.4.3), OlinkAnalyze (3.7.0), data.table (1.15.0),
- 202 ImerTest (3.1), Ime4 (1.1)³⁶, readxl (1.4.3), dplyr (1.1.4), ggplot2 (3.4.3), reshape2 (1.4.4),
- 203 ggrepel (0.9.5), forcats (1.0.0), ggsci (3.0.0), RColorBrewer (1.1.3), optimx (2023-10.21), minqa
- 204 (1.2.6), dfoptim (2023.1.0), survey (4.2.1), scales (1.3.0), ggnewscale (0.4.10), ggpubr (0.6.0),
- 205 gplots (3.1.31), psych (2.4.1), MuMIn (1.47.5), vegan (2-6-6.1), NatParksPalettes (0.2.0), and
- 206 ggfortify (0.4.16).
- 207 The following packages and versions were used for analysis in Python v3.10.9: $pandas^{41}(1.5.3)$,
- 208 sklearn^{42,43} (1.3.2), numpy⁴⁴ (1.23.5), and shap⁴⁰(0.43.0).
- 209
- 210 Formulas
- 211 TP: True Positive
- 212 TN: False Negative
- 213 FP: False Positive
- 214 FN: False Negative
- 215 Accuracy = (TP+FN)/(TP+FP+TN+FN)
- 216 Sensitivity=TP/(TP+FN)
- 217 Specificity=TN/(TN+FP)
- 218
- 219
- 220
- 221
- 222
- 223
- 224
- 225

It is made available under a CC-BY-NC-ND 4.0 International license .

11

226 **RESULTS**

227 Subject Characteristics

Details of the subjects' characteristics are shown in Table 1. A total of 1,106 individuals (CD n = 636; UC n=470) from 17 medical centers were included. CD patients were on average, 42.26 years old and 62% of the CD patients were female. UC patients were on average 43.98 years old and 50.95% of the total UC patients were female.

Specific proteins differentiate the proteomic profiles of Crohn's disease and Ulcerative
 colitis

234 The studied plasma proteome dataset includes measures of 2,920 protein levels across 1,106 patients from the Crohn's and Colitis Foundation dataset¹ (Table 1, Fig 1). We initially ran 235 236 a principal component analysis (PCA) (Fig 2A) and an analysis of similarities (ANOSIM) which 237 revealed that the global proteomes of CD and UC do not differ (p=0.21, R=0.004). We then conducted a Protein Wide Association Study (PWAS) analysis adapted from previous study ^{38,45} 238 239 to filter for proteins measured at significantly different levels between CD and UC. Age and sex 240 were included as fixed effects with disease severity as random effect. The PWAS-based 241 approach identified thirteen proteins that were significant after Bonferroni correction (Table 2, 242 Fig 2B, Table S1). Five of these proteins, INSL5, IL12B, IL12AB, HRG, and LY96 were more 243 abundant in CD relative to UC; in contrast, eight proteins, FGF19, EPCAM, NOS2, GPA33, 244 GUC2A, GRAB, FGFR4, MMP10 were more abundant in UC relative to CD (Fig S1). 245 Performing an ANOSIM test and PCA analysis (Fig 2C) on the proteins identified via PWAS 246 after multiple test correction revealed that there was significant a difference between the CD 247 and UC cohorts (p=0.001, R=0.1247). 248 Grouping Specific proteins improve prediction of Crohn's disease and Ulcerative Colitis 249 We aimed to determine whether the PWAS identified proteomic features could lead to 250 improved differentiation of CD and UC via ML classification. To do this we trained random forest

251 models on feature sets composed of different combinations of proteomic features and patient

It is made available under a CC-BY-NC-ND 4.0 International license .

12

252 features (age, sex, disease severity). We generated three features sets which contained the 253 following: 1) the entire proteome and patient features ("Full Feature Set"), 2) subset of 254 proteomic features which only included the thirteen significant proteins (e.g., INSL5) identified 255 by the PWAS and patient features (referred to as "PWAS and Patient Features"), and 3) just the 256 thirteen significant proteins identified by the PWAS without patient features ("PWAS Features"). 257 Models trained on the "Full Feature Set" had significantly higher specificity, but significantly 258 lower accuracy, sensitivity, and ROC-AUC scores compared to the other two feature sets (Fig 259 **3A-D, Table 3).** Models trained on "PWAS and Patient Features" and just "PWAS Features" 260 were significantly more accurate and sensitive than models trained on the "Full Feature Set," 261 they did not differ significantly in performance from each other (Fig 3A-D). Next, we interrogated 262 the ML models using SHapley Additive exPlanations (SHAP) analysis, which can infer feature 263 importance, to determine if patient features were important for model performance. Interestingly, 264 SHAP feature importance analysis suggested patient features were not informative, where Age, 265 Disease Severity, and Sex were the ranked as the three least important features in the "PWAS 266 and Patient Features" model suggesting that the patient features contributed the least to model 267 performance (Fig 2B, 4AB, S1). Notably, interrogating the ML models revealed that the three 268 most important features including granzyme B, Insulin-like peptide 5 (INSL5), and Interleukin 269 12B (IL12B) were conserved between models. (Fig 4AB). This demonstrates that PWAS-based 270 approaches act as a filter for identifying more informative features which in turn improve 271 prediction performance. 272 273

- 274
- 275
- 276
- 277

It is made available under a CC-BY-NC-ND 4.0 International license .

13

278 **DISCUSSION**

279 Accurately classifying subtypes of IBD poses a significant clinical challenge. 280 Identification of noninvasive biomarkers that can increase the accuracy of diagnosing and 281 subtyping IBD is a major unmet need. There has been a growing interest in using proteomics to 282 identify new biomarkers for the differentiation of IBD; however, these studies have been limited by the number of proteins measured^{46,47}. Here, we used a highly sensitive proximity extension 283 284 assay and measured 2920 proteins in the plasma of IBD patients. Protein wide association 285 analysis with age and sex as fixed effects identified 13 proteins that are significantly different 286 between CD and UC. Further, using used multiple feature sets in random forest models, we 287 discovered that PWAS identified proteins could distinguish between CD and UC with high 288 accuracy and sensitivity. Taken together, we have identified a novel set of proteins in blood that 289 can potentially complement other existing biomarkers to accurately subtype IBD.

290 Machine learning algorithms are increasingly being utilized to analyze medical data to 291 diagnose diseases, predict their severity, and monitor their progression. Recent work on 292 diagnosing IBD using ML approaches has also been successful, achieving high levels of performance^{12,48–50}. For instance, supervised learning models on RNA sequencing data enabled 293 294 CD and UC differentiation¹². Similarly, deep learning networks have been used on endoscopic images to accurately predict the severity of the disease in IBD^{48,49}. Although proteomic datasets 295 296 have been generated in IBD, the application of ML techniques to analyze such datasets has been limited⁴⁷. Furthermore, previous IBD-focused proteomics datasets have measured smaller 297 298 panels of proteins^{47,51–53}. We used a combined PWAS-based feature selection and ML models 299 on a large dataset of proteins to identify novel signatures that could accurately subtype IBD. 300 Importantly, in contrast to previous studies that have primarily focused on inflammatory markers, 301 we analyzed proteins that are involved in a diverse array of processes including, hormonal

It is made available under a CC-BY-NC-ND 4.0 International license .

14

regulation, inflammation, cancer, and brain gut axis. Our findings suggest that PWAS based ML
 approaches could improve subtyping of IBD patients.

304 Several proteins in our cohort have been validated by other IBD studies focused on differentiating CD from UC. A study by Bourgonje et al. also employed a proximity extension 305 assay (Olink) and measured 92 proteins identifying FGF19, IL12B, and MMP10 to be 306 differentially abundant between CD and UC⁵³. In another study by Di Narzo et al., the authors 307 308 used a SOMAmer-based capture array to measure protein levels in plasma (n=244) and 309 discovered that Granzyme B, FGF19, and MMP10 were downregulated in CD relative to UC, mirroring our results⁵². Importantly, our findings combined with others have identified FGF19 and 310 311 MMP10 as consistent plasma-based biomarkers which can be used differentiate CD from UC^{52,53}. 312

313 Among the 13 differentially abundant proteins significant in the PWAS after multiple 314 correction, Granzyme B, IL12B, and INSL5 were the most informative for model prediction (Fig **4A-B**). INSL5, to date, has not been measured in similar proteomics studies focused on IBD^{52,53}. 315 Notably, depletion of *INSL5* transcripts in mucosal tissue has been associated with IBD⁵⁴, and 316 317 our study further implicates the INSL5 peptide as differentially abundant between CD and UC. 318 INSL5 is a peptide hormone that is expressed in the colonic epithelium ^{54–56}. Because INSL5 is 319 a microbially regulated molecule, it is possible that UC, but not CD, specific microbes alter its production⁵⁷. Indeed, both bacterial and fungal microbiota are known to be different between UC 320 and CD^{58–60}. Another possible reason for the decreased abundance of INSL5 in UC relative to 321 322 CD is the loss of colonic epithelial cells due to ulceration, a prominent feature of UC⁶¹. Future 323 studies are needed to elucidate how INSL5 is regulated and the mechanisms by which INSL5 modulates the severity of the disease^{54,62}. In addition to INSL5, Granzyme B was also a 324 325 powerful predictive feature and was elevated in UC. Granzyme B is a serine protease released by lymphocytes which can trigger apoptosis^{63,64}. Similar to our findings, Di Narzo et al. identified 326

15

elevated Granzyme B protein levels in CD compared to UC⁵². Further, levels of Granzyme B
have been reported to predict treatment responses in IBD as its levels are significantly lower in
responders compared to non-responder populations⁶⁵. While these initial findings are promising,
it is unclear how the levels of these targets fluctuate throughout disease specific treatments and
subtype. Future studies utilizing longitudinal samples are needed to ascertain its association
with IBD subtypes.

333 Our study has several strengths: (1) We utilized a relatively large sample size with 334 patients from 17 different medical centers; (2) Because the SPARC cohort follows standard 335 guidelines, it allows investigators to maintain consistency in both data and bio-sample collection; 336 (3) Our data analysis controlled for multiple parameters including age and sex: (4) We assessed 337 over 2,900 proteins using the Olink platform, enabling us to capture differences across a wide 338 range. Limitations include: (1) absence of a healthy cohort, (2) a single time point of blood 339 collection, (3) and need for validation in non-North American cohorts. Future studies including a 340 healthy control group and longitudinal data would enable exploration of the complex nature of 341 IBD, focusing on the complex spatial-temporal dynamics of IBD location and flare up. This 342 would add important context for leveraging proteins such as INSL5 whether alone or in 343 combination with other markers to differentiate between CD and UC.

Overall, the results of this study provide evidence that applying a PWAS-based approach to filter for potentially relevant proteins improves ML model predication for differentiation between CD and UC. Importantly, the informative biomarkers identified in our study have not been previously examined in the context of differentiating CD from UC. We speculate that this approach may identify new targets for biomarker research and improve mechanistic understanding of disease states.

350

352 References:

- Raffals LE., Saha S., Bewtra M., Norris C., Dobes A., Heller C., et al. The Development and Initial Findings of A Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD). *Inflammatory Bowel Diseases* 2022;**28**(2):192–9. Doi: 10.1093/ibd/izab071.
- Kaplan GG. The global burden of IBD: from 2015 to 2025. *Nat Rev Gastroenterol Hepatol* 2015;**12**(12):720–7. Doi: 10.1038/nrgastro.2015.150.
- Duryee MJ., Ahmad R., Eichele DD., Hunter CD., Mitra A., Talmon GA., et al. Identification of Immunoglobulin G Autoantibody Against Malondialdehyde-Acetaldehyde Adducts as a Novel Serological Biomarker for Ulcerative Colitis. *Clin Transl Gastroenterol* 2022;**13**(4):e00469. Doi: 10.14309/ctg.00000000000469.
- Soriano CR., Powell CR., Chiorean MV., Simianu VV. Role of hospitalization for
 inflammatory bowel disease in the post-biologic era. *World J Clin Cases* 2021;9(26):7632–
 42. Doi: 10.12998/wjcc.v9.i26.7632.
- The global, regional, and national burden of inflammatory bowel disease in 195 countries
 and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study
 2017. Lancet Gastroenterol Hepatol 2019;5(1):17–30. Doi: 10.1016/S2468-1253(19)303334.
- Xavier RJ., Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease.
 Nature 2007;**448**(7152):427–34. Doi: 10.1038/nature06005.
- Mitropoulou M-A., Fradelos EC., Lee KY., Malli F., Tsaras K., Christodoulou NG., et al.
 Quality of Life in Patients With Inflammatory Bowel Disease: Importance of Psychological
 Symptoms. *Cureus* n.d.;**14**(8):e28502. Doi: 10.7759/cureus.28502.
- Bernstein CN., Nabalamba A. Hospitalization, Surgery, and Readmission Rates of IBD in Canada: A Population-Based Study. Official Journal of the American College of Gastroenterology | ACG 2006;101(1):110.
- Panaccione R. Mechanisms of Inflammatory Bowel Disease. *Gastroenterol Hepatol (N Y)* 2013;9(8):529–32.
- 380 10. Graham DB., Xavier RJ. Pathway Paradigms Revealed from the Genetics of Inflammatory
 381 Bowel Disease. *Nature* 2020;**578**(7796):527–39. Doi: 10.1038/s41586-020-2025-2.
- 382 11. Guan Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel
 383 Disease. *J Immunol Res* 2019;**2019**:7247238. Doi: 10.1155/2019/7247238.
- 12. Park S-K., Kim S., Lee G-Y., Kim S-Y., Kim W., Lee C-W., et al. Development of a Machine
 Learning Model to Distinguish between Ulcerative Colitis and Crohn's Disease Using RNA
 Sequencing Data. *Diagnostics (Basel)* 2021;**11**(12):2365. Doi:
 10.3390/diagnostics11122365.
- 13. von Stein P., Lofberg R., Kuznetsov NV., Gielen AW., Persson J., Sundberg R., et al.
 Multigene Analysis Can Discriminate Between Ulcerative Colitis, Crohn's Disease, and
 Irritable Bowel Syndrome. *Gastroenterology* 2008;**134**(7):1869–81. Doi:
 10.1053/j.gastro.2008.02.083.
- Tontini GE., Vecchi M., Pastorelli L., Neurath MF., Neumann H. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. *World J Gastroenterol* 2015;**21**(1):21–46. Doi: 10.3748/wjg.v21.i1.21.
- 15. Kanazawa A., Yamana T., Okamoto K., Sahara R. Risk Factors for Postoperative Intra abdominal Septic Complications after Bowel Resection in Patients with Crohn's Disease.
 Diseases of the Colon & Rectum 2012;**55**(9):957. Doi: 10.1097/DCR.0b013e3182617716.
- 16. Lewis RT., Maron DJ. Efficacy and Complications of Surgery for Crohn's Disease.
 Gastroenterol Hepatol (N Y) 2010;6(9):587–96.

- 400 17. Guo K., Ren J., Li G., Hu Q., Wu X., Wang Z., et al. Risk factors of surgical site infections in 401 patients with Crohn's disease complicated with gastrointestinal fistula. *Int J Colorectal Dis* 402 2017;**32**(5):635–43. Doi: 10.1007/s00384-017-2751-6.
- 403 18. Post S., Betzler M., von Ditfurth B., Schürmann G., Küppers P., Herfarth C. Risks of
 404 intestinal anastomoses in Crohn's disease. *Ann Surg* 1991;**213**(1):37–42.
- 405
 405 19. Singh S., Nguyen GC. Management of Crohn's Disease After Surgical Resection.
 406 *Gastroenterology Clinics of North America* 2017;**46**(3):563–75. Doi:
 407 10.1016/j.gtc.2017.05.011.
- 408 20. Kavic SM., Basson MD. Complications of endoscopy. *The American Journal of Surgery* 2001;**181**(4):319–32. Doi: 10.1016/S0002-9610(01)00589-X.
- Prideaux L., De Cruz P., Ng SC., Kamm MA. Serological Antibodies in Inflammatory Bowel
 Disease: A Systematic Review. *Inflammatory Bowel Diseases* 2012;**18**(7):1340–55. Doi:
 10.1002/ibd.21903.
- WALKER LJ., ALDHOUS MC., DRUMMOND HE., SMITH BRK., NIMMO ER., ARNOTT
 IDR., et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are
 associated with disease severity but not NOD2/CARD15 mutations. *Clin Exp Immunol*2004;**135**(3):490–6. Doi: 10.1111/j.1365-2249.2003.02392.x.
- 23. Zhou G., Song Y., Yang W., Guo Y., Fang L., Chen Y., et al. ASCA, ANCA, ALCA and Many
 More: Are They Useful in the Diagnosis of Inflammatory Bowel Disease? *Digestive Diseases*2016;**34**(1–2):90–7. Doi: 10.1159/000442934.
- 420 24. Reese GE., Constantinides VA., Simillis C., Darzi AW., Orchard TR., Fazio VW., et al.
 421 Diagnostic Precision of Anti-Saccharomyces cerevisiae Antibodies and Perinuclear
 422 Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease. Official Journal of the
 423 American College of Gastroenterology | ACG 2006;101(10):2410.
- 25. Oikonomou KA., Kapsoritakis AN., Theodoridou C., Karangelis D., Germenis A., Stefanidis
 I., et al. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease:
 association with pathophysiology of inflammation, established markers, and disease activity. *J Gastroenterol* 2012;47(5):519–30. Doi: 10.1007/s00535-011-0516-5.
- 428 26. Barnes EL., Burakoff R. New Biomarkers for Diagnosing Inflammatory Bowel Disease and
 429 Assessing Treatment Outcomes. *Inflamm Bowel Dis* 2016;**22**(12):2956–65. Doi:
 430 10.1097/MIB.0000000000003.
- 431 27. Jukic A., Bakiri L., Wagner EF., Tilg H., Adolph TE. Calprotectin: from biomarker to biological
 432 function. *Gut* 2021;**70**(10):1978–88. Doi: 10.1136/gutjnl-2021-324855.
- 433 28. Barnes EL., Liew C-C., Chao S., Burakoff R. Use of blood based biomarkers in the
 434 evaluation of Crohn's disease and ulcerative colitis. *World J Gastrointest Endosc*435 2015;7(17):1233–7. Doi: 10.4253/wjge.v7.i17.1233.
- 436 29. Wang T., Yang S., Long Y., Li Y., Wang T., Hou Z. Olink proteomics analysis uncovers the
 437 landscape of inflammation-related proteins in patients with acute compartment syndrome.
 438 *Front Immunol* 2023;**14**:1293826. Doi: 10.3389/fimmu.2023.1293826.
- 30. Kong T., Qu Y., Zhao T., Niu Z., Lv X., Wang Y., et al. Identification of novel protein
 biomarkers from the blood and urine for the early diagnosis of bladder cancer via proximity
 extension analysis. *J Transl Med* 2024;22:314. Doi: 10.1186/s12967-024-04951-z.
- 442 31. Gong Q., Fu M., Wang J., Zhao S., Wang H. Potential Immune-Inflammatory Proteome
 443 Biomarkers for Guiding the Treatment of Patients with Primary Acute Angle-Closure
 444 Glaucoma Caused by COVID-19. *J Proteome Res* 2024. Doi:
 445 10.1021/acs.jproteome.4c00325.
- 32. Diaz-Canestro C., Chen J., Liu Y., Han H., Wang Y., Honoré E., et al. A machine-learning
 algorithm integrating baseline serum proteomic signatures predicts exercise responsiveness
 in overweight males with prediabetes. *Cell Rep Med* 2023;**4**(2):100944. Doi:
- 449 10.1016/j.xcrm.2023.100944.

- 33. Berisha V., Krantsevich C., Hahn PR., Hahn S., Dasarathy G., Turaga P., et al. Digital
 medicine and the curse of dimensionality. *NPJ Digit Med* 2021;**4**:153. Doi: 10.1038/s41746021-00521-5.
- 453 34. Pattern Recognition. 2008.
- 454 35. Pudjihartono N., Fadason T., Kempa-Liehr AW., O'Sullivan JM. A Review of Feature
 455 Selection Methods for Machine Learning-Based Disease Risk Prediction. *Front Bioinform*456 2022;**2**:927312. Doi: 10.3389/fbinf.2022.927312.
- 457 36. Bates D., Mächler M., Bolker B., Walker S. Fitting Linear Mixed-Effects Models Using Ime4.
 458 *Journal of Statistical Software* 2015;**67**:1–48. Doi: 10.18637/jss.v067.i01.
- 459 37. Bastarache L., Denny JC., Roden DM. Phenome-Wide Association Studies. *JAMA* 2022;**327**(1):75–6. Doi: 10.1001/jama.2021.20356.
- 38. Gorelik AJ., Paul SE., Karcher NR., Johnson EC., Nagella I., Blaydon L., et al. A PhenomeWide Association Study (PheWAS) of Late Onset Alzheimer Disease Genetic Risk in
 Children of European Ancestry at Middle Childhood: Results from the ABCD Study. *Behav Genet* 2023;**53**(3):249–64. Doi: 10.1007/s10519-023-10140-3.
- 30. Oksanen J., Simpson GL., Kindt R., Legendre P., Minchin PR., O'Hara RB., et al. Vegan □:
 community ecology package. *Http://Vegan.r-Forge.r-ProjectOrg/* 2010.
- 467 40. Lundberg SM., Lee S-I. A Unified Approach to Interpreting Model Predictions. *Advances in* 468 *Neural Information Processing Systems*, vol. 30. Curran Associates, Inc.; 2017.
- 469 41. The pandas development team. pandas-dev/pandas: Pandas 2024. Doi:
 470 10.5281/zenodo.10957263.
- 471 42. Pedregosa F., Varoquaux G., Gramfort A., Michel V., Thirion B., Grisel O., et al. Scikit-learn:
 472 Machine Learning in Python. *Journal of Machine Learning Research* 2011;**12**(85):2825–30.
- 473 43. Pedregosa F., Varoquaux G., Gramfort A., Michel V., Thirion B., Grisel O., et al. Scikit-learn:
 474 Machine Learning in Python 2018. Doi: 10.48550/arXiv.1201.0490.
- 44. Harris CR., Millman KJ., van der Walt SJ., Gommers R., Virtanen P., Cournapeau D., et al.
 Array programming with NumPy. *Nature* 2020;**585**(7825):357–62. Doi: 10.1038/s41586-0202649-2.
- 478 45. Brandes N., Linial N., Linial M. PWAS: proteome-wide association study-linking genes and phenotypes by functional variation in proteins. *Genome Biol* 2020;**21**(1):173. Doi: 10.1186/s13059-020-02089-x.
- 481 46. Zhao JH., Stacey D., Eriksson N., Macdonald-Dunlop E., Hedman ÅK., Kalnapenkis A., et
 482 al. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated
 483 disease risk and therapeutic targets. *Nat Immunol* 2023;**24**(9):1540–51. Doi:
 484 10.1038/s41590-023-01588-w.
- 485 47. Kalla R., Adams AT., Bergemalm D., Vatn S., Kennedy NA., Ricanek P., et al. Serum
 486 proteomic profiling at diagnosis predicts clinical course, and need for intensification of
 487 treatment in inflammatory bowel disease. *Journal of Crohn's and Colitis* 2021;**15**(5):699–
 488 708. Doi: 10.1093/ecco-jcc/jjaa230.
- 48. Chierici M., Puica N., Pozzi M., Capistrano A., Donzella MD., Colangelo A., et al.
 490 Automatically detecting Crohn's disease and Ulcerative Colitis from endoscopic imaging.
 491 *BMC Medical Informatics and Decision Making* 2022;**22**(6):300. Doi: 10.1186/s12911-022492 02043-w.
- 49. Takenaka K., Ohtsuka K., Fujii T., Negi M., Suzuki K., Shimizu H., et al. Development and
 494 Validation of a Deep Neural Network for Accurate Evaluation of Endoscopic Images From
 495 Patients With Ulcerative Colitis. *Gastroenterology* 2020;**158**(8):2150–7. Doi:
 496 10.1053/j.gastro.2020.02.012.
- 497 50. Seeley EH., Washington MK., Caprioli RM., M'Koma AE. Proteomic Patterns of Colonic
 498 Mucosal Tissues Delineate Crohn's Colitis and Ulcerative Colitis. *Proteomics Clin Appl*499 2013;7(0):10.1002/prca.201200107. Doi: 10.1002/prca.201200107.

- 500 51. Gisbert JP., Chaparro M. Clinical Usefulness of Proteomics in Inflammatory Bowel Disease:
 501 A Comprehensive Review. *J Crohns Colitis* 2019;**13**(3):374–84. Doi: 10.1093/ecco502 jcc/jjy158.
- 503 52. Di Narzo AF., Brodmerkel C., Telesco SE., Argmann C., Peters LA., Li K., et al. High 504 Throughput Identification of the Plasma Proteomic Signature of Inflammatory Bowel
 505 Disease. Journal of Crohn's and Colitis 2019;13(4):462–71. Doi: 10.1093/ecco-jcc/jjy190.
- 506 53. Bourgonje AR., Hu S., Spekhorst LM., Zhernakova DV., Vich Vila A., Li Y., et al. The Effect
 507 of Phenotype and Genotype on the Plasma Proteome in Patients with Inflammatory Bowel
 508 Disease. *Journal of Crohn's and Colitis* 2022;**16**(3):414–29. Doi: 10.1093/ecco-jcc/jjab157.
- 509 54. Skok DJ., Hauptman N., Jerala M., Zidar N. Expression of Cytokine-Coding Genes BMP8B,
 510 LEFTY1 and INSL5 Could Distinguish between Ulcerative Colitis and Crohn's Disease.
 511 Genes (Basel) 2021;12(10):1477. Doi: 10.3390/genes12101477.
- 512 55. Thanasupawat T., Hammje K., Adham I., Ghia J-E., Del Bigio MR., Krcek J., et al. INSL5 is a 513 novel marker for human enteroendocrine cells of the large intestine and neuroendocrine 514 tumours. *Oncology Reports* 2013;**29**(1):149–54. Doi: 10.3892/or.2012.2119.
- 515 56. Liu C., Kuei C., Sutton S., Chen J., Bonaventure P., Wu J., et al. INSL5 is a high affinity
 516 specific agonist for GPCR142 (GPR100). *J Biol Chem* 2005;**280**(1):292–300. Doi:
 517 10.1074/jbc.M409916200.
- 57. Lee YS., De Vadder F., Tremaroli V., Wichmann A., Mithieux G., Bäckhed F. Insulin-like
 peptide 5 is a microbially regulated peptide that promotes hepatic glucose production. *Mol Metab* 2016;5(4):263–70. Doi: 10.1016/j.molmet.2016.01.007.
- 58. Jain U., Ver Heul AM., Xiong S., Gregory MH., Demers EG., Kern JT., et al. Debaryomyces
 is enriched in Crohn's disease intestinal tissue and impairs healing in mice. *Science*2021;**371**(6534):1154–9. Doi: 10.1126/science.abd0919.
- 524 59. Schirmer M., Franzosa EA., Lloyd-Price J., McIver LJ., Schwager R., Poon TW., et al.
 525 Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. *Nat*526 *Microbiol* 2018;3(3):337–46. Doi: 10.1038/s41564-017-0089-z.
- 527 60. Franzosa EA., Sirota-Madi A., Avila-Pacheco J., Fornelos N., Haiser HJ., Reinker S., et al.
 528 Gut microbiome structure and metabolic activity in inflammatory bowel disease. *Nature*529 *Microbiology* 2019;4(2):293–305. Doi: 10.1038/s41564-018-0306-4.
- 61. A K., P G. Ulcerative colitis: understanding its cellular pathology could provide insights into
 novel therapies. *Journal of Inflammation (London, England)* 2020;**17**. Doi: 10.1186/s12950020-00246-4.
- 62. Pustovit RV., Zhang X., Liew JJ., Praveen P., Liu M., Koo A., et al. A Novel Antagonist
 Peptide Reveals a Physiological Role of Insulin-Like Peptide 5 in Control of Colorectal
 Function. ACS Pharmacol Transl Sci 2021;4(5):1665–74. Doi: 10.1021/acsptsci.1c00171.
- 536 63. Trapani JA., Sutton VR. Granzyme B: pro-apoptotic, antiviral and antitumor functions. *Curr* 537 *Opin Immunol* 2003;**15**(5):533–43. Doi: 10.1016/s0952-7915(03)00107-9.
- 64. Kim TJ., Koo JS., Kim SJ., Hong SN., Kim YS., Yang S-K., et al. Role of IL-1ra and
 Granzyme B as biomarkers in active Crohn's disease patients. *Biomarkers* 2018;23(2):161–
 6. Doi: 10.1080/1354750X.2017.1387933.
- 541 65. Heidari P., Haj-Mirzaian A., Prabhu S., Ataeinia B., Esfahani SA., Mahmood U. Granzyme B
 542 PET Imaging for Assessment of Disease Activity in Inflammatory Bowel Disease. *Journal of*543 *Nuclear Medicine* 2024. Doi: 10.2967/jnumed.123.267344.
- 544
- 545

546

It is made available under a CC-BY-NC-ND 4.0 International license .

548			
549			
550			
551			
552			
553			
554			
555			
556			
557			
558			

559 Figures



Figure 1. Sample processing and analysis pipeline. Blood plasma samples were collected
and processed as described in the methods and materials. Differentially abundant proteins were
identified in the PWAS analysis. Protein abundance was used as features for the machine
learning models to classify CD from UC.

It is made available under a CC-BY-NC-ND 4.0 International license .

21







•Bonferonni Cutoff •FDR Cutoff •Not Significant

568 Figure 2. PWAS analysis enables separation of the proteomic profiles of Ulcerative colitis

- and Crohn's disease. A) Principal Component Analysis (PCA) of the global proteomics profiles
- 570 of Crohn's disease and Ulcerative colitis. B) Volcano plot where the x axis is the calculated beta
- and the y axis is the negative log₁₀ of the unadjusted p-value; green and labeled points had a
- 572 Bonferroni adjusted p-value of less than 0.0000171 (used in Fig 1B), orange points had an FDR
- adjusted p value of less than .05, and purple points represent proteins with a p-value > .05.
- 574 Negative beta values are associated with Crohn's disease and positive beta values are
- 575 associated with Ulcerative colitis. C) PCA of the proteomics profile identified by the PWAS
- analysis. Ellipses represent 95% confidence bounds around group centroids.
- 577

It is made available under a CC-BY-NC-ND 4.0 International license .



It is made available under a CC-BY-NC-ND 4.0 International license .

582 Figure 3. Specific proteins improve machine learning based differentiation of CD and UC.

- 583 A) Effect of feature set on model accuracy. B) Effect of feature set on model sensitivity. C) Effect
- of feature set on model specificity. D) Effect of feature set on model ROC-AUC. ***P<.001,
- 585 ANOVA with Tukey's post hoc test.

It is made available under a CC-BY-NC-ND 4.0 International license .



599

600 Figure 4. Clinical Features do not improve model performance. A) SHAP beeswarm plot of 601 the validation dataset indicating feature importance in random forest models trained on patient associated features (Age, Sex, Disease Severity) and the thirteen proteins which are 602 603 significantly associated with Crohn's disease and Ulcerative colitis. B) SHAP beeswarm plot of 604 the validation dataset indicating feature importance in random forest models trained on just the 605 thirteen proteins which are significantly associated with Crohn's disease and ulcerative colitis. 606 Features are sorted in order of predicted importance in a descending manner. 607

608

It is made available under a CC-BY-NC-ND 4.0 International license .



- 612 Bonferroni correction (Fig 1B).
- 613
- 614
- 615

It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1. Cohort Breakdown

		Crohn's	Ulcerative colitis	p value
		Disease		
Number		636	470	
Age in years,		42.26 (14.25)	43.979 (14.6)	.414
mean (SD)				
Sex (%)	Female	397 (62)	240 (50.95)	.0002
Disease	Remission	228 (35.8)	205 (43.5)	<.0001
Severity (%)	Mild	156 (24.5)	154 (32.7)	
	Moderate	237 (37.2)	88 (18.6)	
	Severe	15 (2.35)	23 (4.88)	

It is made available under a CC-BY-NC-ND 4.0 International license .

28

632 Table 2. PWAS Results

Protein Name	Average	Average	PWAS	PWAS	PWAS	PWAS
	Level in	Level in	Standardized	p-value	FDR	Bonferroni
	Crohn's	Ulcerative	Beta		Adjusted	Adjusted p-
	Disease	Colitis			p-value	value
	0.143	-0.93	-0.453	1.73E-	5.05E-18	5.05E-18
INSL5				21		
	1.772	0.683	-0.455	7.15E-	1.04E-17	2.09E-17
IL12B				21		
	-1.398	-0.648	0.564	9.66E-	9.40E-17	2.82E-16
FGF19				20		
	1.982	0.839	-0.387	6.39E-	4.66E-16	1.87E-15
IL12A-IL12B				19		
			0.494	7.49E-	4.37E-14	2.19E-13
EPCAM	-0.735	-0.087		17		
	0.550	1.131	0.390	1.76E-	8.59E-10	5.15E-09
NOS2				12		
	-1.307	-0.515	0.286	4.72E-	1.97E-09	1.38E-08
GPA33				12		
HRG	0.492	0.322	-1.040	4.58E-11	1.67E-08	1.34E-07
GUC2A	0.099	0.349	0.847	5.94E-11	1.93E-08	1.73E-07
	1.016	1.838	0.225	1.81E-	5.30E-08	5.30E-07
GRAB				10		
	-0.333	-0.054	0.578	2.50E-	6.65E-08	7.31E-07
FGFR4				10		
	I					

It is made available under a CC-BY-NC-ND 4.0 International license .

		0.612	0.991	0.429	2.03E-	4.94E-07	5.93E-06
	MMP10				09		
		0.383	0.242	-0.863	2.89E-	6.48E-07	8.42E-06
	LY96				09		
633							
634							
635							
636							
637							
638							
639							
640							
641							
642							
643							
644							
645							
646							
647							
648							
649							
650							
651							
652							
653	Table 3. Average	Machine L	earning Mode	el Results			

It is made available under a CC-BY-NC-ND 4.0 International license .

Metric	Full Feature	PWAS and Patient	Patient Features	
	Set	Features		
Accuracy	66.29%	73.48%	72.6%	
Sensitivity	0.36	0.64	0.63	
Specificity	0.88	0.80	0.79	
ROC-AUC	0.62	0.73	0.73	